Results 51 to 60 of about 494,545 (309)

Identification of novel neutralizing determinants for protection against HCV

open access: yesHepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua   +12 more
wiley   +1 more source

Engineering Microbial Particles for Next‐Generation Biomedical Platforms

open access: yesAdvanced Science, EarlyView.
Microbe‐derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus‐like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a ...
Yuting Li   +7 more
wiley   +1 more source

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

open access: yesHepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie   +17 more
wiley   +1 more source

Association of Hepatitis C Virus (HCV) Infection and Human Leukocyte Antigens (HLA)

open access: yesDiyala Journal of Medicine, 2019
Back ground: Several previous reports on the association between hepatitis C virus (HCV) infection and certain human leukocyte antigens (HLA) have yielded controversial results.
Abdul-Razak SH Hasan   +1 more
doaj   +2 more sources

Predictive value of HBeAg titer dynamics for HBsAg clearance in pediatric chronic hepatitis B

open access: yesFrontiers in Pediatrics
IntroductionAchieving functional cure of chronic hepatitis B (CHB), characterized by the loss of HBV DNA and HBsAg, remains challenging in adults but demonstrates higher success rates in children.
Sukjin Hong   +8 more
doaj   +1 more source

ASSESSMENT OF THE ACTUAL AND POTENTIAL EPIDEMIOLOGYCAL SITUATION OF THE VIRAL HEPATITIS C AND B BASED BY LABORATORY DATA IN THE “DOCTOR PARAMONOV’S CLINIC” IN SARATOV CITY AND SARATOV REGION

open access: yesПаёми Сино, 2017
Objective: Study of the prevalence of the viral hepatitis C and viral hepatitis B in the territory of Saratov City and Saratov Region, analysis of the revealed cases and discussion of laboratory diagnostics issues.
V.V. NIKITINA   +3 more
doaj   +1 more source

Targeting p21‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

open access: yesAdvanced Science, EarlyView.
Schematic illustration of a biomimetic SKEV@AAV platform targeting p21‐high senescent Kupffer cells (sKCs) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). p21‐high sKCs accumulate in the PVTT microenvironment and establish an immunosuppressive, SASP‐rich environment that facilitates tumor cell proliferation and immune evasion.
Na Ta   +10 more
wiley   +1 more source

Emergence of highly profibrotic and proinflammatory Lrat+Fbln2+ HSC subpopulation in alcoholic hepatitis

open access: yesHepatology, EarlyView., 2022
Lrat+ quiescent hepatic stellate cells (qHSC) give rise to Lrat+Fbln2+ activated HSC (aHSC) in alcohol‐associated hepatitis and this subpopulation is highly profibrotic, inflammatory, and immunoregulatory based on their single cell transcriptomic profile. Abstract Background and Aims Relative roles of HSCs and portal fibroblasts in alcoholic hepatitis (
Steven Balog   +12 more
wiley   +1 more source

Weekly HBsAg Decline Dynamics During Combination Therapy with Interferon and Nucleos(t)ide Analogs: A Retrospective Real-World Study

open access: yesViruses
Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) loss, remains a major goal in chronic hepatitis B (CHB) management. HBsAg kinetics during interferon (IFN)-based therapy are associated with treatment response and prognosis, but ...
Ziyuan Yi   +9 more
doaj   +1 more source

Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution

open access: yesKaohsiung Journal of Medical Sciences, 2015
Hepatitis B virus surface antigen (HBsAg) levels reflect disease status and can predict the clinical response to antiviral treatment; however, the emergence of HBsAg mutant strains has become a challenge.
Ta-Wei Liu   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy